Success Metrics

Clinical Success Rate

66.7%

Based on 4 completed trials

Completion Rate

67%(4/6)

Active Trials

2(25%)

Results Posted

100%(4 trials)

Terminated

2(25%)

Phase Distribution

Ph not_applicable

13%

Ph phase_1

38%

Ph phase_2

25%

Ph phase_3

13%

Ph phase_4

13%

Phase Distribution

Early Stage

Mid Stage

Late Stage

Phase Distribution8 total trials

Phase 1Safety & dosage

3(37.5%)

Phase 2Efficacy & side effects

2(25.0%)

Phase 3Large-scale testing

1(12.5%)

Phase 4Post-market surveillance

1(12.5%)

N/ANon-phased studies

1(12.5%)

Highest Phase Reached

Phase 4

Trial Status & Enrollment

Completion Rate

66.7%

4 of 6 finished

Non-Completion Rate

33.3%

2 ended early

Currently Active

trials recruiting

Total Trials

all time

Status Distribution

Active(2)

Completed(4)

Terminated(2)

Detailed Status

Completed4

Recruiting2

Terminated2

Development Timeline

Analytics

Development Status

Total Trials

Active

Success Rate

66.7%

Most Advanced

Phase 4

Trials by Phase

Phase 13 (37.5%)

Phase 22 (25.0%)

Phase 31 (12.5%)

Phase 41 (12.5%)

N/A1 (12.5%)

Trials by Status

recruiting225%

completed450%

terminated225%

Recent Activity

2 active trials

Showing 5 of 8

recruitingphase_4

Intravenous Thrombolysis Combined With Tirofiban in Acute Ischemic Stroke

NCT07290751

completedphase_1

Study of Recombinant Protein Vaccine Formulations Against COVID-19 in Healthy Adults 18 Years of Age and Older

NCT04537208

terminatedphase_1

Study of mRNA Vaccine Formulation Against COVID-19 in Healthy Adults 18 Years of Age and Older

NCT04798027

recruitingphase_2

PG2 Injection for the Treatment of moderate-to Severe Fatigue in Breast Cancer Patients

NCT05440227

terminatedphase_3

Study of a Candidate Clostridium Difficile Toxoid Vaccine in Subjects at Risk for C. Difficile Infection

NCT01887912

View all 8 trials

Clinical Trials (8)

Showing 8 of 8 trials

NCT07290751Phase 4

Intravenous Thrombolysis Combined With Tirofiban in Acute Ischemic Stroke

Recruiting

NCT04537208Phase 1

Study of Recombinant Protein Vaccine Formulations Against COVID-19 in Healthy Adults 18 Years of Age and Older

Completed

NCT04798027Phase 1

Study of mRNA Vaccine Formulation Against COVID-19 in Healthy Adults 18 Years of Age and Older

Terminated

NCT05440227Phase 2

PG2 Injection for the Treatment of moderate-to Severe Fatigue in Breast Cancer Patients

Recruiting

NCT01887912Phase 3

Study of a Candidate Clostridium Difficile Toxoid Vaccine in Subjects at Risk for C. Difficile Infection

Terminated

NCT01230957Phase 2

Study of Different Formulations of a Clostridium Difficile Toxoid Vaccine Given at Three Different Schedules in Adults

Completed

NCT00585325Not Applicable

Instilled Lidocaine vs Placebo for Pain Management During Vacuum Assisted Closure (VAC) Dressing Changes

Completed

NCT01542619Phase 1

A Safety and Pharmacokinetics Study of a Recombinant Fusion Protein Linking Coagulation Factor VIIa With Albumin (rVIIa-FP) in Healthy Male Volunteers

Completed

All 8 trials loaded

Drug Details

Intervention Type: OTHER
Total Trials: 8